Hereditary Haemorrhagic Telangiectasia (HHT-WG)
Clinical Outcome Measures
Outcome Measures were developed and implemented by the Hereditary Haemorrhagic Telangiectasia Working Group (HHT-WG) to maximise the number of patients receiving good care. This Clinical Position Statement is based on the 5 Outcome Measures selected by members of the VASCERN HHT-WG.
European Reference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT)
March 13 2023
Shovlin CL, Buscarini E, Kjeldsen AD, Mager HJ, Sabba C, Droege F, Geisthoff U, Ugolini S, Dupuis-Girod S. Haematologica. 2019 Feb;104(2):e85-e86. doi: 10.3324/haematol.2018.209791.